TY - JOUR
T1 - Personalized and translational approach for malignant brain tumors in the era of precision medicine
T2 - the strategic contribution of an experienced neurosurgery laboratory in a modern neurosurgery and neuro-oncology department
AU - Campanella, Rolando
AU - Guarnaccia, Laura
AU - Caroli, Manuela
AU - Zarino, Barbara
AU - Carrabba, Giorgio
AU - La Verde, Nicla
AU - Gaudino, Chiara
AU - Rampini, Angela
AU - Luzzi, Sabino
AU - Riboni, Laura
AU - Locatelli, Marco
AU - Navone, Stefania Elena
AU - Marfia, Giovanni
N1 - Copyright © 2020 Elsevier B.V. All rights reserved.
PY - 2020/10/15
Y1 - 2020/10/15
N2 - Personalized medicine (PM) aims to optimize patient management, taking into account the individual traits of each patient. The main purpose of PM is to obtain the best response, improving health care and lowering costs. Extending traditional approaches, PM introduces novel patient-specific paradigms from diagnosis to treatment, with greater precision. In neuro-oncology, the concept of PM is well established. Indeed, every neurosurgical intervention for brain tumors has always been highly personalized. In recent years, PM has been introduced in neuro-oncology also to design and prescribe specific therapies for the patient and the patient's tumor. The huge advances in basic and translational research in the fields of genetics, molecular and cellular biology, transcriptomics, proteomics, and metabolomics have led to the introduction of PM into clinical practice. The identification of a patient's individual variation map may allow to design selected therapeutic protocols that ensure successful outcomes and minimize harmful side effects. Thus, clinicians can switch from the "one-size-fits-all" approach to PM, ensuring better patient care and high safety margin. Here, we review emerging trends and the current literature about the development of PM in neuro-oncology, considering the positive impact of innovative advanced researches conducted by a neurosurgical laboratory.
AB - Personalized medicine (PM) aims to optimize patient management, taking into account the individual traits of each patient. The main purpose of PM is to obtain the best response, improving health care and lowering costs. Extending traditional approaches, PM introduces novel patient-specific paradigms from diagnosis to treatment, with greater precision. In neuro-oncology, the concept of PM is well established. Indeed, every neurosurgical intervention for brain tumors has always been highly personalized. In recent years, PM has been introduced in neuro-oncology also to design and prescribe specific therapies for the patient and the patient's tumor. The huge advances in basic and translational research in the fields of genetics, molecular and cellular biology, transcriptomics, proteomics, and metabolomics have led to the introduction of PM into clinical practice. The identification of a patient's individual variation map may allow to design selected therapeutic protocols that ensure successful outcomes and minimize harmful side effects. Thus, clinicians can switch from the "one-size-fits-all" approach to PM, ensuring better patient care and high safety margin. Here, we review emerging trends and the current literature about the development of PM in neuro-oncology, considering the positive impact of innovative advanced researches conducted by a neurosurgical laboratory.
U2 - 10.1016/j.jns.2020.117083
DO - 10.1016/j.jns.2020.117083
M3 - Review article
C2 - 32784071
VL - 417
SP - 117083
JO - Journal of the Neurological Sciences
JF - Journal of the Neurological Sciences
SN - 0022-510X
ER -